Quintiles IMS Holdings Inc. has formed a new collaborative initiative with four top biopharma companies to ferret out real-world data on the use of cancer treatments across seven top European markets. The Collaboration for Oncology Data in Europe, or CODE, is funded both by QuintilesIMS and four initial partners with an interest in the data: Bristol-Myers Squibb Co., Eli Lilly and Co., Merck KGaA and Pfizer Inc.